

Capstone Therapeutics Corp.  
Form 8-K  
June 17, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report: June 12, 2014 (Date of earliest event reported)

CAPSTONE THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

000-21214  
(Commission File Number)

86-0585310  
(I.R.S. Employer  
Identification No.)

1275 West Washington Street, Suite 104, Tempe, Arizona  
(Address of principal executive offices)

85281  
(Zip Code)

Registrant's telephone number, including area code:  
(602) 286-5520

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 5 - Corporate Governance and Management

Item 5.07. Submission of Matters to a Vote of Security Holders.

Annual Meeting of Stockholders

(a) Our Annual Meeting of Stockholders was held on June 12, 2014 with a quorum in attendance.

(b) At the Annual Meeting, stockholders elected our nominees for Class I and Class II Directors, approved an Amendment to the Company's 2005 Equity Incentive Plan, increasing the number of shares of Common Stock available for grant, by 500,000 shares, and ratified the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2014. The certified results of the matters voted upon at the meeting, which are more fully described in our Proxy Statement, are as follows:

Proposal 1: Proposal to Elect a Class I Director For Term Expiring in Year 2016 and a Class II Director For Term Expiring in Year 2017:

Director Nominees	Number of Shares		
	FOR	WITHHELD	BROKER NON-VOTES
Eric W. Fangmann (Class I)	23,585,414	927,170	10,889,483
John M. Holliman (Class II)	23,483,336	1,029,248	10,889,483

Proposal 2: Amendment to the Company's 2005 Equity Incentive Plan, increasing the number of shares of Common Stock available for grant by 500,000 shares

Number of Shares			
FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
22,307,350	1,904,344	300,890	10,889,483

Proposal 3: Proposal to Ratify the Appointment of Moss Adams LLP as our Independent Registered Public Accounting Firm for Fiscal Year 2014

Number of Shares		
FOR	AGAINST	ABSTAIN
34,523,414	736,007	142,646

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
10.1	2005 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on May 18, 2006)
10.2	Amendment to 2005 Equity Incentive Plan (Incorporated by reference to Exhibit 99.2 to the Company's Registration Statement on Form S-8 filed with the SEC on May 14, 2009)

10.3 Amendment to 2005 Equity Incentive Plan (Incorporated by reference to Exhibit 99.3 to the Company's Registration Statement on Form S-8 filed with the SEC on June 17, 2014)

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 17, 2014

CAPSTONE THERAPEUTICS CORP.

/s/ John M. Holliman, III  
John M. Holliman, III  
Executive Chairman

---

Exhibit Index

Exhibit No.	Description
10.1	2005 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on May 18, 2006)
10.2	Amendment to 2005 Equity Incentive Plan (Incorporated by reference to Exhibit 99.2 to the Company's Registration Statement on Form S-8 filed with the SEC on May 14, 2009)
10.3	Amendment to 2005 Equity Incentive Plan (Incorporated by reference to Exhibit 99.3 to the Company's Registration Statement on Form S-8 filed with the SEC on June 17, 2014)